Fortress Biotech Announces First Patient Dosed in Multi-Center Phase 2 Study of Triplex for Control of CMV in Patients Undergoing Liver Transplantation Helocyte, a majority-owned subsidiary of Fortress Biotech, is developing Triplex for the prevention and treatment of cytomegalovirus in multiple transplant indications, as well as HIV Clinical trial...

Fortress Biotech Subsidiary Helocyte Announces Option Agreement with City of Hope for Exclusive Worldwide Rights to use a Novel Bispecific CMV/HIV CAR T Cell Therapy (optionally in combination with Triplex) for the Treatment of Adults Living with HIV-1 Recent $11.3 million grant from the California Institute for Regenerative Medicine (CIRM) intended to fund the Phase 1 clinical trial at City of Hope; the Investigational New Drug application for...

Helocyte Announces $3.22 Million Grant from the National Cancer Institute for Triplex Phase 2 Clinical Trial Program Multicenter randomized placebo-controlled trials will evaluate the ability of the cytomegalovirus (“CMV”) vaccine to enhance protective virus-specific immunity in stem cell donors to reduce the risk...

Study Published in American Journal of Hematology Demonstrates First Reported Evidence of Safe and Successful Boosting of Cytomegalovirus Vaccine-Specific T Cell Immunity in a Stem Cell Transplant Recipient Via Vaccination of a Donor with Triplex Phase 2 clinical trial planned to evaluate efficacy of Triplex-vaccinated donors to enhance protective CMV-specific T cell immunity in stem cell transplant recipients Helocyte, Inc., a subsidiary...